Factors Determining in the Treatment of the Effectiveness of CB-154 Acromegaly

HANEW, K., SASAKI, A., SATO, S., SHIMIZU, Y., MURAKAMI, O. and YOSHINAGA, K. Foctors Determining the Effectiveness o f CB-154 in the Treatment o f Acromegaly. Tohoku J. exp. Med., 1983, 139 (1), 91-95 To predict the effectiveness of CB-154 treatment in patients with acromegaly plasma Gil changes induced by CB-154 treatment were compared with Gil responses to TRH or arginine tests performed before the treatment. Fourteen patients with active acromegaly (4 males and 10 females, aged 16-68 years) were given 7.5 to 15 mg of CB-154 daily for 3 weeks or longer. During the treatment 7 of the 14 cases showed significant Gil decreases (20.1 to 86.2%; p<0.05-0.001), and one of the other 7 cases showed a significant Gil increase (30.8%; p<0.005) as compared with Gil values before the treatment. In the remaining 6 cases no significant Gil changes were observed. Before the treatment 12 of the 14 cases showed distinct Gil responses (68-7,033% increase from the basal GH) to the bolus injection of TRH. Ten of these 12 cases also showed an increase in Gil to arginine infusion (62-5,557%). There was a significant relationship between Gil changes induced by CB-154 therapy and logarithmic values of the ratio of TRH-induced Gil increase vs. arginine-induced Gil increase (r=-0.75; p<0.005). Two cases of less responsive type did not show any Gil changes to the treatment. It is concluded that CB-154 treatment is effective only in more responsive type of acromegaly, and especially in cases which are more responsive to TRH and less responsive to arginine. acromegaly; GH; CB-154; TRH; arginine